Avrobio

Geoff MacKay, President and CEO
Cambridge, MA
(NASDAQ: AVRO)
Avrobio’s mission is to free people from a lifetime of genetic disease with a single dose of gene therapy. We aim to halt or reverse disease throughout the body by driving durable expression of functional protein, even in hard-to-reach tissues and organs including the brain, muscle, and bone. Our clinical-stage programs include Fabry disease, Gaucher disease, and cystinosis, and we also are advancing a program in Pompe disease. AVROBIO is powered by the plato™ gene therapy platform, our foundation designed to scale gene therapy worldwide.
www.avrobio.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions